Adial Pharmaceuticals, Inc. Deferred Federal, State and Local, Tax Expense (Benefit)
Adial Pharmaceuticals, Inc. (ADIL) reported Deferred Federal, State and Local, Tax Expense (Benefit) of $14.10 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for the quarter ending 2019-06-30 was $1.60M.
- Adial Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for the quarter ending 2019-03-31 was $9.70M.
- Adial Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2019 was $14.10M, a 98.59% increase from fiscal 2018.
- Adial Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2018 was $7.10M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 3 month | Deferred Federal, State and Local, Tax Expense (Benefit) 6 month | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2019-12-31 | $14.10M 10-K · filed 2020-03-20 | ||
| 2019-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $11.30M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $9.70M 10-Q · filed 2019-05-13 | ||
| 2018-12-31 | $7.10M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |